A subsequent trial in 25 individuals with established T1D (between 4 months and 2 years post-diagnosis) used a lower dose of ATG (2.5 mg/kg administered as 0.5 mg/kg on day 1 and 2 mg/kg on day 2) and combined the treatment with Granulocyte colony-stimulating factor (GCSF) in line with previous preclinical data [45]. The gene discussed is CSF3; the disease is type 1 diabetes mellitus.